We retrospectively analyzed the percentages and absolute numbers of T cells, natural killer (NK) cells and NK cell subsets in cryopreserved samples of either bone marrow or blood non-T cell-depleted allogeneic MHC-matched hematopoietic grafts. Using flow cytometry, we found higher numbers of NK cells in aphereses than in bone marrow collections. We further investigated the distribution of NK cell subsets, defined by the cell surface expression of MHC class I-specific receptors, in these allogeneic grafts. The distribution of NK cell subsets from the two different origins were similar, with the exception of the CD158a/h + NK cell subset, whose size appeared to be smaller in bone marrow. The search for relations between the numbers of infused cells and post-transplantation events demonstrated that increasing numbers of infused T cells but not NK cells are related with decreased overall survival. Our study highlights the toxicity of infused T cells but not NK cells in allogeneic MHC-matched hematopoietic grafts. These data pave the way for further trials to investigate the effect of NK cell infusion in MHC-matched allogeneic transplantation, and in particular whether ex vivo NK cell expansion and activation may enhance the anti-tumoral effect of the procedure and decrease its morbidity.
Introduction
Allogeneic cell transplantation has now been evaluated for three decades, 1 in a variety of diseases, including malignant and non-malignant disorders. Most of the therapeutic efficacy of allogeneic cell transplantation results from the recognition of host tumor cells by donor-derived immune effectors, ie the graft-versus-leukemia (GVL) effect, initially demonstrated in patients with leukemias or other types of blood malignancies. [2] [3] [4] Recently, additional evidence has been reported, suggesting that a similar anti-tumor effect can participate in the cure of poor-prognostic neoplasias of epithelial origin, such as breast 5 or renal cell carcinomas. 6 Precise identification of cellular effectors that are responsible for the GVL effect remains to be established. However, T cells play an important role in GVL, as demonstrated by the increased incidence of relapse following T cell depletion of the graft in vitro, 7 T cell anergisation in vitro, 8 or increased immunosuppression in vivo. 9 A number of arguments suggest that cell populations other than ␣␤ T cells can also mediate some of the clinical events frequently observed after allogeneic transplantation, including the GVL effect. Along these lines, in a murine model of MHC-incompatible allogeneic bone marrow transplantation, injection of ex vivo activated and expanded ␥␦ T cells has been demonstrated to facilitate engraftment. 10 A role of NK cells in transplantation was initially described in 'hybrid resistance', in which F1 hybrid recipients reject parental bone marrow grafts, while accepting solid tissues. 11, 12 More recently, in a murine model of MHC-incompatible allogeneic bone marrow transplantation, Murphy et al showed that infusion of in vitro IL-2 activated NK cells could prevent the development of graft-versus-host disease (GVHD), exert an anti-tumoral effect against a co-transplanted tumor cell line, and increase survival in recipient mice. [13] [14] [15] The molecular basis for these effects mediated by NK cells in transplantation are being unraveled. Indeed, NK cell activity is controlled by a dynamic balance between engagement of activating receptors and MHC class I-specific inhibitory NK receptors (NKR) expressed on their surface. [16] [17] [18] In humans, MHC class I-specific NKR belong to two distinct groups of molecules: killer cell immunoglobulin (Ig)-like receptors (KIR) are members of a multigenic and multiallelic family of Ig-like molecules, while CD94/NKG2 heterodimers belong to the C-type lectin receptor family. KIR primarily act as receptors for classical MHC class Ia molecules, whereas CD94/NKG2 heterodimers recognize the non-classical MHC class Ib molecules, HLA-E. 16, 18 NKR act as inhibitory receptors when they possess an immunoreceptor tyrosine-based inhibitory motif (ITIM) in their intracytoplasmic domain. Similarly to NKR, human NK cell activating receptors belong to the Ig-like superfamily for the natural cytotoxicity receptors (NCR: NKp30, NKp44, NKp46), or to the lectin-like family (NKG2D). NCR associate with immunoreceptor tyrosine-based activating motif (ITAM) polypeptides (CD3, FcR␥, KARAP/DAP12), whereas NKG2D interact with the DAP10 transducing polypeptide. 19 NCR and NKG2D interact with ligands that are upregulated upon cellular stress and tumor transformation (eg MICA for NKG2D), 20, 21 or virus infection (eg viral hemagglutinins for NKp46). 22 Although NCR represent the major receptors for NK cell cytotoxicity, other molecules such as CD2, CD69, CD44, CD38 and CD244 also enhance NK cell killing. 19 The importance of NK cells and inhibitory NKR engagement by MHC class I molecules has been demonstrated in a number of mouse and human models of MHC-mismatched allogeneic transplantation. Indeed, the rejection of parental bone marrow graft by a F1 hybrid can be abrogated by the transgenic expression of HLA-Cw3 and the cognate KIR (CD158b) in the parental donor and F1 recipient, respectively. 23 Along this line, the treatment of leukemia-bearing mice with F(abЈ) 2 fragments of monoclonal antibody (mAb) against Ly49C and I, as well as adoptive transfer of NK cells treated ex vivo with the same F(abЈ) 2 fragments, resulted in significant increases in mouse survival, demonstrating that blockade of inhibitory MHC class I-specific NKR enhances anti-tumor activity in vivo. 24 In both humans and mice, the presence of KIR/MHC class I incompatibility (KIR epitope incompatibility) between donors and recipients of HLA-mismatched allogeneic transplantation, ie when the donor KIR repertoire fails to recognize the HLA epitopes of the recipient, was recently demonstrated to be associated with anti-leukemic activity of donor-derived NK cell clones. [25] [26] [27] However, in humans, most allogeneic hematopoietic transplantations are performed from phenoidentical or geno-identical donors. Yet, in such situations of MHC-matched transplantation, a role for NK cells in GVL has been also documented. Indeed, IL-2-activated NK cells infused in syngeneic mouse exert a significant GVL effect. 28 Moreover, it has recently been demonstrated, in vivo in the mouse, that NK cells can reject tumor cell lines expressing syngeneic MHC class I molecules. 29, 30 In this study, we analyzed the NK cell and T cell compartments present in hematopoietic bone marrow grafts and aphereses which were infused in adult patients undergoing MHCmatched and non-T cell-depleted allogeneic transplantation.
Methods

Patients and donors
Twenty-seven patients received a MHC-matched non-T celldepleted allogeneic transplant, according to standard eligibility criteria and current protocols at Institut Paoli-Calmettes (IPC). Informed consent was obtained from donors and recipients, prior to inclusion in protocols. Grafts were from genoidentical donors for 24 patients, from a syngeneic donor for one patient, and from pheno-identical donors for two patients. Serological typing was used for MHC class I molecules, and molecular typing was used for MHC class II molecules. Patients were reinfused either with allogeneic bone marrow (n = 18), or with allogeneic peripheral blood progenitor cells (aphereses, n = 9). In the latter situation, donors were mobilized with rhG-CSF prior to apheresis, as previously described. 31, 32 Conditioning regimens and GVHD prophylaxis were as per institutional protocols, depending on diagnosis and disease status. Donor and patient characteristics and major clinical events are described in Table 1 .
Graft characterization
For all donor/patient pairs, cells were harvested and processed according to standard procedures at the IPC Cell Therapy Facility. Freshly collected grafts were analyzed for their content in nucleated cells, hematopoietic progenitors (CD34 + cells) and lymphoid subpopulations (CD3 + cells) by flow cytometry, using standard procedures. 33 For regulatory reasons, and as per institutional protocols, 1 ml samples of the cell suspension were cryopreserved in 2 ml cryotubes, and kept in the vapor phase of liquid nitrogen. The study described below was performed on cells recovered from these thawed samples. It was first validated by comparing CD3
+ cell counts obtained before and after the freeze-thaw process. These values were not statistically different, and further analyses were conducted with thawed graft samples.
Antibodies
The following mouse mAb were used in this study (Table 2) : PE-conjugated anti-CD158a/h (IgG1, EB6), anti-CD158b1/b2/j (IgG1, GL183), anti-CD158e1/e2 (IgG1, ZIN276), anti-CD94 (IgG2a, HP3B1), anti-CD159a (IgG2b, Z199), 34 FITC-conjugated anti-CD3 (IgG1, UCHT1), PC5-conjugated anti-CD16 (IgG1, 3G8) and CD56 (IgG1, NKH.1). These mAb and their isotype-matched negative control mAb were purchased from Beckman Coulter Immunotech (Marseille, France).
Flow cytometric analysis of lymphocyte populations
Cryopreserved graft samples were analyzed with three-color flow cytometry to determine the percentages of total T cells, total NK cells, as well as NK cell subsets in the grafts. Briefly, thawed hematopoietic cells were incubated with the indicated PE-labeled anti-NKR, FITC-labeled anti-CD3 and the PC5-labeled anti-CD16 and anti-CD56 mAb, in PBS supplemented with 1% BSA. The pelleted cells were analyzed with an EPICS XL II cytometer (Beckman-Coulter, Margency, France). The analysis was focused on lymphocytes, identified by their forward and right angle scatter features. At least 10 000 events were collected in the lymphocyte gate and analyzed. NK cells were defined as CD3 − CD16
+ CD56 + cells. Five distinct NK cell subsets were defined as NK cells expressing at least one of the following NKR: CD94, CD159a, CD158a/h, CD158b1/b2/j or CD158e1/e2. Absolute numbers of infused cells per kg were computed from the total numbers of viable mononuclear cells, the percentages of lymphocytes in the graft sample, and the recipient weight (cell dose).
Statistical analyses
Graphic representation of the NKR cell surface expression on NK cells obtained from aphereses and bone marrow transplants, as well as the descriptive statistics of these cell compartments were obtained by using Prism Graphpad software (San Diego, CA, USA). Comparison of distributions was done with a Mann-Whitney U test.
The relation between the infused doses of NK and T cells, and post-transplantation clinical events, ie the development of acute GVHD and overall survival, was studied using multivariate analysis. We used a proportional hazard model (Cox model) to analyze the relation between these variables and the post-transplantation survival. Logistic regression was used to study the relation with acute GVHD. All data were computed using SPSS for Windows software (SPSS, Chicago, IL, USA). Multivariate analyses included CD34 + cell dose, log (T cell dose) and log (NK cell dose), or CD34 + cell dose, log (T cell dose) and log (NK subset cell dose). A logarithmic transformation was used for T, NK and NK cell subset doses, because of the log normal distribution of these variables. As all cell doses were significantly different depending on the nature of the graft (bone marrow vs aphereses), we added these data as an indicator variable. The role of T cells on survival was further investigated with Kaplan-Meier analysis: two groups of patients were arbitrarily clustered through the median value of the T cell dose and overall survival of the two groups was compared using a log-rank test.
Results
NK cells in apheresis and bone marrow hematopoietic transplants
Availability of clinical grade and recombinant hematopoietic growth factors has led to the evaluation of apheresis as an alternative to bone marrow in hematopoietic transplantation. Several reports have recently been published, demonstrating that similarly to previous observations in the autologous setting, the use of allogeneic blood cells in place of bone marrow cells resulted in faster neutrophil and platelet recovery. 32, [35] [36] [37] However, because of the higher immune cell content in blood Leukemia grafts, the incidence and severity of chronic GVHD were increased, so that benefits and disadvantages appear to be balanced and the role of allogeneic aphereses as an alternative to bone marrow has not been clearly established yet. In this study, apheresis and bone marrow allogeneic grafts were characterized for their content in hematopoietic progenitors (CD34 + cells), as well as in T lymphocytes and NK cells, using flow cytometric analysis. Absolute cell numbers were further expressed per kilogram of recipient weight (cell doses). As shown in Table 3 , grafts of bone marrow or blood origin differ significantly by their contents in hematopoietic progenitors, T lymphocytes and NK cells, an observation consistent with previous studies. 32, 37 Indeed, all cell doses infused within aphereses were significantly higher than those within bone marrow samples (Table 3 ). In particular, patients infused with apheresis received on average 20-fold more NK cells than patients infused with bone marrow transplants.
Phenotypic analysis of NK cell subsets in hematopoietic transplants
NK cells from bone marrow as well as from apheresis are mostly CD16
dim NK cells (Figure 1a and b) . However, as previously described in peripheral blood NK cells, two distinct subsets can be identified in graft samples, according to their CD56 surface expression, ie CD56 dim and CD56 bright NK cells. These phenotypic correlates suggest that NK cells infused within allogeneic transplantation harbor a heterogeneity similar to that observed in peripheral blood of healthy donors. 38 We further investigated the NKR repertoire expressed on NK cells obtained from apheresis and bone marrow, using threecolor flow cytometry (Figures 2 and 3 ). This analysis shows that bone marrow collections and aphereses contain NK cells that express the CD94/NKG2A-B heterodimers and KIR molecules. In both types of graft, KIR molecules were expressed only on CD16 + CD56 dim NK cells (data not shown), as previously described for unmanipulated peripheral blood lymphocytes. 39 The distribution of NK cell subsets expressing CD94/NKG2A-B heterodimers and KIR molecules did not differ significantly between either type of graft, with the exception of the CD158a/h + NK cell subset whose size was smaller in bone marrow. 
Incidence of NK and T cell doses on posttransplantation events
Using multivariate analysis, we investigated the relation between NK and T cell doses, and the occurrence of posttransplantation events (Table 4 ). The relation between NK cell doses (total NK cells or NK cell subsets) or T cell doses and acute GVHD was not demonstrated in this study. The role of NK cells in the development of chronic GVHD could not be statistically explored because only five of the patients who were alive 100 days after transplantation developed chronic GVHD.
While the relation between T cell depletion and the incidence of the GVHD/GVL effects is well established, 7, 40 no firm relation between T cell dose and survival has been reported yet. Despite the small number of donor/recipient pairs, we demonstrated a statistically significant relationship between the infused T cell dose and patient survival: patients receiving high doses of T cells (Ͼ 0.3 × 10 8 T cells/kg) exhibit a decreased survival, as shown with Cox multivariate (Table 4) and Kaplan-Meier analyses (Figure 4 ). This observation does not reflect the origin of allogeneic cells, and thus a potential bias in patient selection, as the group with high T cell doses includes both recipients of aphereses and recipients of bone marrow cells.
Discussion
The present analysis documents the effects of donor T and NK cells present in hematopoietic grafts, in the clinical events which follow allogeneic MHC-matched transplantation. Despite the limited number of donor/recipient pairs studied, our data show that infusion of increasing doses of donor T cells is deleterious for post-transplantation survival. The selection of distinct T cell clones in each individual, and the difficulty of predicting TCR cross-reactivity both contribute to the toxicity associated with adoptive transfer of polyclonal T cells in humans, even in a MHC-matched setting. In contrast, the manipulation of non-conventional lymphocytes, and in particular NK cells, seems attractive for adoptive transfer. Indeed, NK cells are much less diverse in their repertoire of activating cell surface receptors than T cells for the TCR repertoire and NK cell reactivity is tightly controlled by the recognition of stress-induced cell surface molecules (ie MICA), as well as by the absence of recognition of self-MHC class I molecules.
Figure 2
Phenotypic analysis of NK cell subsets present in allogeneic hematopoietic grafts. A representative frozen allogeneic apheresis sample was stained for three-color flow cytometry as described in Methods. Samples were gated on CD3
+ lymphocytes. NK cell subsets are defined as NK cells expressing at least one of the following NKR: CD94, CD159a, CD158a/h, CD158b1/b2/j or CD158e1/e2. The number in the upper left quadrant indicates the percentage of NK cell subset.
These properties predict an absence of toxicity of NK cell infusions against normal donor tissues in an allogeneic MHCmatched setting.
In the present retrospective study of 27 MHC-matched allogeneic cell transplantations, no relation could be established between NK cell doses and patient survival or acute GVHD. This observation suggests that infusions of low doses (Ͻ 0.9 × 10 8 /kg) of bone marrow or apheresis NK cells are not toxic. Yet, this result does not preclude that donor NK cells may play a role in post-transplantation events as the number of patients included in this study may be too limited to demonstrate such a relation. The peripheral blood CD16 + CD56 dim NK cell subset (Ϸ 90% NK cells) has been described as exerting potent cytolytic function in vitro, with a low proliferation and cytokine production potential. In contrast, the CD16 dim/-CD56 bright NK cell subset (Ϸ 10% NK cells), exerts weaker cytolytic activity, proliferates more vigorously in response to cytokines such as IL-2 and secretes inflammatory cytokines. 38 Our finding that NK cells infused in this study comprise both CD16 +
CD56
dim and CD16 dim/-CD56 bright subsets (Figure 1 ) implies that NK cells infused within allogeneic bone marrow and aphereses transplantation contain both cytotoxic and cytokine producing NK cells. However, the analysis of the distribution of NKR + on NK cells demonstrates a difference of the distribution pattern of the CD158a/h + NK cell subset between both types of graft. The significance of the lower proportion of the CD158a/h + NK cell subset in bone marrow remains unclear. An orderly acquisition of NKR has been described on Leukemia mouse NK cells. [41] [42] It is thus possible that shaping of the NKR repertoire is also sequential in humans, with CD158a/h being expressed later in the course of NK cell maturation. Nevertheless, the present phenotypic characterization supports the fact that NK cells present in hematopoietic grafts, and thus infused in patients during the course of allogeneic transplantation, are equipped with multiple NKR, and are therefore capable of interactions with MHC class I molecules.
Experimental settings used to demonstrate a role for NK cells in murine models of transplantation differ from therapeutic human transplantation protocols: (1) murine models that demonstrate a positive role for NK cells in survival, GVHD and GVL, use IL-2-activated NK cells, and (2) NK cell doses are approximately 10-to 20-fold higher than NK cell doses infused in this study (1 × 10 7 to 2 × 10 7 IL-2-activated NK cells were infused in mice, a cell dose approximately equivalent to 5 × 10 8 to 1 × 10 9 NK cells/kg in humans). [13] [14] [15] Thus, it remains to be determined whether high doses (Ͼ10 8 /kg) of activated human NK cells may similarly improve clinical outcome of human allogeneic transplantations.
Our study suggests that given the difficulty of controling donor T cell toxicity, transplantation biologists now have tools to explore the role of non-conventional lymphocytes involved in innate immunity, particularly the NK cell populations, in human allogeneic transplantation, and to establish whether NK cells may play a positive role in MHC-matched transplantation, similar to that described in the haplo-identical setting. 28 While in a MHC-matched setting, donor NK cells Multivariate analyses including CD34 + cell dose, log (T cell dose) and log (NK cell or NK cell subset dose), were used to investigate the relationship between the infused T and NK cells and post-transplantation events, ie overall survival and the development of acute GVHD. P values are indicated and P Ͻ 0.05 was considered as a threshold for a statistically significant relation ( * ).
should be antagonized by recognition of host MHC class I molecules, a number of factors can alter these interactions, thus providing an incentive to study the phenotype and function of the donor NK cell compartment. First, reactivity of donor NK cells against host tumor cells may be the result of a downregulation of MHC class I-specific molecules, as described in certain types of cancers. 43 In such circumstances, inhibitory signals delivered via NKR engagement are not impaired, leading to NK cell cytolytic activity and cytokine
Figure 4
Post-transplantation survival. The Kaplan-Meier curves represent overall survival for recipients of non-T cell-depleted allogeneic transplantation from a MHC-matched donor, who received a dose of T cells above (dotted line) or below (solid line) the median value for this parameter (0.3 × 10 8 T cells/kg). Survival for the two groups was compared using a log-rank test.
secretion. Second, activation of donor NK cells may also occur when the peptides presented by MHC class I molecules expressed on host tumor cells alter appropriate interactions with NKR. Indeed, the nature of the peptides exposed in the groove of molecules is critical for the affinity of KIR/MHC class I interactions 44, 45 . Finally, the cell surface expression of ligands for NCR/NKG2D can be up-regulated on host tumor cells, leading to the selective attack by donor NK cells. 46, 47 Along these lines, it has recently been demonstrated that mouse NK cells could mediate the rejection of tumor cell lines such as EL4 (thymoma) and B16-BL6 (melanoma) when they are transfected with NKG2D ligands, eg RAE-1 and H60. 29, 30 These data demonstrate that NK cells can reject tumor cells expressing these ligands, despite their expression of MHC class I molecules, thus demonstrating that NK cell anti-tumoral response can also occur in the HLA-matched setting.
Clinical trials have already demonstrated that the infusion of autologous IL-2-activated adherent NK cells is feasible in humans and well tolerated. 48, 49 It is thus tempting to design innovative therapeutic strategies that aim at amplifying and activating NK cells in vivo or in vitro to improve the antitumor effect of allogeneic cell transplantation while minimizing their toxicities.
(EV, VP) and by Institut Paoli-Calmettes. The authors also thank the Beckman-Coulter Company for its contribution to the conduct of this work.
